CareTrust REIT, Inc. 8-K

What Happened
CareTrust REIT, Inc. (CTRE) announced it completed a public offering of common stock: 12,500,000 firm shares and the full exercise of a 1,875,000‑share option. The offering price to the underwriters was $40.225 per share. The underwriters were Wells Fargo Securities, LLC and J.P. Morgan Securities LLC; the forward purchasers were Wells Fargo Bank, N.A. and JPMorgan Chase Bank, N.A. The underwriters notified the company on May 20, 2026 that they would exercise the option in full, and the Option Offering closed on May 21, 2026. In connection with the option, the forward sellers borrowed and sold an aggregate of 1,875,000 shares on May 21, 2026. The company filed legal opinion letters from DLA Piper LLP (US) regarding the validity of the optional shares.

Key Details

• Firm shares sold: 12,500,000 common shares.
• Option shares exercised: 1,875,000 common shares (full exercise).
• Offering price: $40.225 per share.
• Approximate gross proceeds (before fees/expenses): 12,500,000 × $40.225 = $502,812,500 (firm) + 1,875,000 × $40.225 = $75,421,875 (option) = $578,234,375 total.
• Important dates: Underwriters elected option on May 20, 2026; Option Offering closed May 21, 2026. Forward sale agreements were entered in connection with the optional shares.

Why It Matters
This transaction raises a substantial amount of capital for CareTrust (approximately $578.2 million gross before fees and expenses), which can be used for general corporate purposes such as debt repayment, acquisitions, or working capital (the filing does not specify use of proceeds). The new shares increase the company’s outstanding common stock and therefore dilute existing shareholders’ ownership percentage. The use of forward sale arrangements and borrowed shares to satisfy the option indicates the optional shares were sold into the market via established financing and settlement mechanisms; DLA Piper’s legal opinion was filed to confirm the validity of the issued optional shares. Investors should watch subsequent disclosures for the company’s stated use of proceeds and any impact on per‑share metrics.